AC IMMUNE SA (ACIU) 2.36 -0.04 (-1.67%)
2.36 -0.04 (-1.67%)
CH0329023102 - Common Stock - After market: 2.27 -0.09 (-3.81%)
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ...
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s patient imaged...
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical...
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on...
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
AC Immune to Present at the Jefferies London Healthcare Conference
LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...
AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s...
AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome
Interim analysis expected around year-end 2022, informing Phase 2 startTrial progressing with regulatory clearances in the UK and also now in SpainPlanned...
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease
AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from...
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent
Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human...
AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases
Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalitiesIntegrating its precision medicine...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for a breakdown of the biggest pre-market stock movers for Tuesday and the news that has them moving.
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences...
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Three clinical readouts delivered year to date; four more expected by year-endFirst patient dosed with anti-Abeta vaccine ACI-24.060 in Phase 1b/2 ABATE...
AC Immune Holds Annual General Meeting of Shareholders
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision...